Published in EMBO Rep on January 06, 2006
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol (2008) 1.54
Comprehensive analysis of host cellular interactions with human papillomavirus E6 proteins identifies new E6 binding partners and reflects viral diversity. J Virol (2012) 1.28
Cancer associated human papillomaviruses. Curr Opin Virol (2012) 1.25
Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology (2012) 1.23
Papillomavirus E6 oncoproteins. Virology (2013) 1.21
HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog (2012) 1.16
Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog (2011) 1.10
Interferon-β induces cellular senescence in cutaneous human papilloma virus-transformed human keratinocytes by affecting p53 transactivating activity. PLoS One (2012) 0.94
The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol (2013) 0.94
Recurrent respiratory papillomatosis. Otolaryngol Clin North Am (2012) 0.92
Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol (2011) 0.92
Cutaneous human papillomavirus type 38 E7 regulates actin cytoskeleton structure for increasing cell proliferation through CK2 and the eukaryotic elongation factor 1A. J Virol (2011) 0.91
E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol (2011) 0.90
HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition. Virology (2013) 0.89
IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization. Mol Cell Biol (2011) 0.89
Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants. Cancer Med (2014) 0.88
NF-kappaB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis. J Virol (2011) 0.87
Genus beta human papillomavirus E6 proteins vary in their effects on the transactivation of p53 target genes. J Virol (2014) 0.83
Epstein - Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α. PLoS Pathog (2013) 0.83
β-HPV 5 and 8 E6 disrupt homology dependent double strand break repair by attenuating BRCA1 and BRCA2 expression and foci formation. PLoS Pathog (2015) 0.82
Downregulation of Toll-Like Receptor 9 Expression by Beta Human Papillomavirus 38 and Implications for Cell Cycle Control. J Virol (2015) 0.82
A humanized mouse model of HPV-associated pathology driven by E7 expression. PLoS One (2012) 0.80
Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers (Basel) (2016) 0.79
Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related microRNAs: additional evidence in HPV-induced tumorigenesis. J Cancer Res Clin Oncol (2016) 0.78
Oncoprotein E7 from beta human papillomavirus 38 induces formation of an inhibitory complex for a subset of p53-regulated promoters. J Virol (2013) 0.77
UV Radiation Activates Toll-like Receptor 9 Expression in Primary Human Keratinocytes, an Event Inhibited by Human Papillomavirus Type 38 E6 and E7 Oncoproteins. J Virol (2017) 0.75
Effect of Infliximab on the UVB-Induced Apoptosis of Keratinocytes Infected by HPV38 E6/E7. ISRN Dermatol (2013) 0.75
Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses. Cancer Epidemiol Biomarkers Prev (2017) 0.75
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Classification of papillomaviruses. Virology (2004) 14.16
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer (2003) 8.01
Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer (2004) 6.67
p73: Friend or foe in tumorigenesis. Nat Rev Cancer (2002) 3.30
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci (2000) 2.55
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med (2002) 2.48
Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr (2003) 2.32
The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol (2003) 1.81
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol (2003) 1.33
Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol (1994) 1.14
Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol (2005) 0.99
Human cytomegalovirus induces drug resistance and alteration of programmed cell death by accumulation of deltaN-p73alpha. J Biol Chem (2002) 0.95
p53 mutations are common in human papillomavirus type 38-positive non-melanoma skin cancers. Cancer Lett (2004) 0.93
p73-dependent apoptosis through death receptor: impairment by human cytomegalovirus infection. Cancer Res (2005) 0.90
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat (2007) 12.98
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene (2002) 7.04
Chapter 1: HPV in the etiology of human cancer. Vaccine (2006) 6.61
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res (2006) 4.00
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res (2007) 2.88
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res (2006) 2.76
The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett (2006) 2.37
DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene (2002) 2.27
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res (2005) 2.24
Genetics of lung-cancer susceptibility. Lancet Oncol (2010) 2.24
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Air pollution and risk of lung cancer in a prospective study in Europe. Int J Cancer (2006) 2.17
Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature (2006) 2.09
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell (2009) 2.09
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res (2003) 2.08
Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat (2002) 1.99
Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol (2012) 1.96
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
On the origin of G --> T transversions in lung cancer. Mutat Res (2003) 1.89
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog (2011) 1.89
Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest (2010) 1.88
Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol (2011) 1.85
Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res (2009) 1.84
Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol (2009) 1.82
The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol (2003) 1.81
Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79
Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol (2010) 1.79
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran. Gut (2010) 1.71
TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol (2007) 1.70
MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer (2011) 1.70
The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology (2004) 1.69
Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol (2013) 1.66
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2009) 1.63
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer (2012) 1.63
Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Cancer Lett (2011) 1.62
Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol (2006) 1.61
MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol (2009) 1.56
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50
249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene (2005) 1.49
Biospecimen reporting for improved study quality (BRISQ). J Proteome Res (2011) 1.48
Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor. J Biol Chem (2008) 1.46
Massively regulated genes: the example of TP53. J Pathol (2010) 1.46
The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch (2010) 1.44
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett (2008) 1.44
In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology (2009) 1.43
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res (2007) 1.41
Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr Opin Oncol (2013) 1.40
International efforts to develop biospecimen best practices. Cancer Epidemiol Biomarkers Prev (2010) 1.38
Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer (2011) 1.36
Development of a sensitive and specific multiplex PCR method combined with DNA microarray primer extension to detect Betapapillomavirus types. J Clin Microbiol (2007) 1.36
Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer (2010) 1.35
G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis (2010) 1.34
Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One (2007) 1.34
Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat (2010) 1.32
Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol (2004) 1.32
Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst (2013) 1.29
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res (2007) 1.27
Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol (2010) 1.26
Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell (2008) 1.26
Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol (2012) 1.26
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer (2013) 1.25
The role of TP53 in Cervical carcinogenesis. Hum Mutat (2003) 1.23
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol (2013) 1.22
Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett (2009) 1.22
Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect (2008) 1.22
Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer (2004) 1.21
Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci U S A (2007) 1.19
Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol (2010) 1.17
TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res (2006) 1.16
Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A (2002) 1.16
Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev (2006) 1.15
Mutational analysis of the SARS virus Nsp15 endoribonuclease: identification of residues affecting hexamer formation. J Mol Biol (2005) 1.15
DNA adducts and lung cancer risk: a prospective study. Cancer Res (2005) 1.14
High-efficiency ferroelectric-film solar cells with an n-type Cu₂O cathode buffer layer. Nano Lett (2012) 1.13
miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol (2012) 1.13
Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells. Virology (2004) 1.13
Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene (2005) 1.13
Aberrant DNA methylation links cancer susceptibility locus 15q25.1 to apoptotic regulation and lung cancer. Cancer Res (2010) 1.13